Adverum to Present at Cantor Global Healthcare Conference
September 18 2018 - 4:10PM
Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene
therapy company targeting unmet medical needs in serious rare and
ocular diseases, today announced the company will be participating
in the upcoming Cantor Global Healthcare Conference in New York,
NY.
Adverum’s management is scheduled to present on
Tuesday, October 2, 2018 at 11:30am Eastern Time. Interested
parties may access a live and archived webcast of the presentation
on the “Investors” section of the company’s website at:
www.adverum.com. The webcast will be available on the company’s
website for at least two weeks following the event.
About Adverum Biotechnologies,
Inc.Adverum is a clinical-stage gene therapy company
targeting unmet medical needs in serious rare and ocular diseases.
Adverum has a robust pipeline that includes product candidates
designed to treat rare diseases alpha-1 antitrypsin (A1AT)
deficiency and hereditary angioedema (HAE) as well as wet
age-related macular degeneration (wAMD). Leveraging a
next-generation adeno-associated virus (AAV)-based directed
evolution platform, Adverum generates product candidates designed
to provide durable efficacy by inducing sustained expression of a
therapeutic protein. Adverum has collaboration agreements with
Regeneron Pharmaceuticals to research, develop, and commercialize
gene therapy products for ophthalmic diseases and Editas Medicine
to explore the delivery of genome editing medicines for the
treatment of inherited retinal diseases. Adverum’s core
capabilities include clinical development and in-house
manufacturing expertise, specifically in process development and
assay development. For more information please visit
www.adverum.com.
Investor and Media Inquiries:
Katherine Bock
Vice President Investor Relations & Corporate Communications
Adverum Biotechnologies, Inc.
650-656-9347
kbock@adverum.com
Adverum Biotechnologies (NASDAQ:ADVM)
Historical Stock Chart
From Aug 2024 to Sep 2024
Adverum Biotechnologies (NASDAQ:ADVM)
Historical Stock Chart
From Sep 2023 to Sep 2024